Prothena Corp Public LTD CO PRTA
We take great care to ensure that the data presented and summarized in this overview for PROTHENA CORP PUBLIC LTD CO is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRTA
View all-
Eco R1 Capital, LLC San Francisco, CA11.6MShares$107 Million7.5% of portfolio
-
Black Rock Inc. New York, NY3.86MShares$35.5 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.69MShares$33.9 Million0.01% of portfolio
-
Armistice Capital, LLC New York, NY2.24MShares$20.6 Million0.44% of portfolio
-
State Street Corp Boston, MA1.86MShares$17.1 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA1.74MShares$16 Million3.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.4MShares$12.9 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY1.1MShares$10.1 Million0.67% of portfolio
-
Geode Capital Management, LLC Boston, MA964KShares$8.87 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX865KShares$7.96 Million0.0% of portfolio
Latest Institutional Activity in PRTA
Top Purchases
Top Sells
About PRTA
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Insider Transactions at PRTA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Jan 15
2025
|
William P Scully |
SELL
Bona fide gift
|
Indirect |
12,000
-20.34%
|
-
|
|
Jan 14
2025
|
William P Scully |
BUY
Open market or private purchase
|
Direct |
100,000
+11.96%
|
$1,200,000
$12.79 P/Share
|
|
Jan 03
2025
|
William P Scully |
SELL
Bona fide gift
|
Direct |
1,000
-0.16%
|
-
|
|
Jan 02
2025
|
William P Scully |
SELL
Bona fide gift
|
Direct |
13,200
-2.03%
|
-
|
|
Dec 31
2024
|
William P Scully |
BUY
Open market or private purchase
|
Direct |
32,000
+1.58%
|
$416,000
$13.25 P/Share
|
|
Dec 20
2024
|
William P Scully |
SELL
Bona fide gift
|
Indirect |
40,000
-40.4%
|
-
|
|
Dec 20
2024
|
William P Scully |
SELL
Bona fide gift
|
Direct |
500
-0.08%
|
-
|
|
Dec 20
2024
|
William P Scully |
BUY
Open market or private purchase
|
Direct |
2,000
+0.32%
|
$30,000
$15.91 P/Share
|
|
Dec 19
2024
|
William P Scully |
SELL
Bona fide gift
|
Direct |
681,000
-52.48%
|
-
|
|
Dec 18
2024
|
William P Scully |
BUY
Open market or private purchase
|
Direct |
73,436
+5.36%
|
$954,668
$13.93 P/Share
|
|
Dec 18
2024
|
William P Scully |
BUY
Bona fide gift
|
Direct |
430,000
+25.99%
|
-
|
|
Jan 24
2024
|
Karin L Walker Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$170,000
$34.0 P/Share
|
|
Jan 24
2024
|
Karin L Walker Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$65,000
$13.53 P/Share
|
|
Dec 20
2023
|
Karin L Walker Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,000
-66.78%
|
$185,000
$37.07 P/Share
|
|
Dec 20
2023
|
Karin L Walker Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$65,000
$13.53 P/Share
|
|
Nov 30
2023
|
Karin L Walker Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$170,000
$34.0 P/Share
|
|
Nov 30
2023
|
Karin L Walker Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$65,000
$13.53 P/Share
|
|
Oct 25
2023
|
Karin L Walker Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,000
-75.54%
|
$205,000
$41.31 P/Share
|
|
Oct 25
2023
|
Karin L Walker Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$65,000
$13.53 P/Share
|
|
Oct 11
2023
|
Brandon S. Smith Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,000
-94.45%
|
$188,000
$47.18 P/Share
|
Last 12 Months Summary
| Bona fide gift | 430K shares |
|---|---|
| Open market or private purchase | 207K shares |
| Bona fide gift | 748K shares |
|---|